NASDAQ: XBITXbiotech Inc Stock
$8.21+0.14 (+1.73%)
Updated Apr 25, 2024
XBIT Price
$8.21
Fair Value Price
$6.57
Market Cap
$250.00M
52 Week Low
$3.05
52 Week High
$9.96
P/E
-10.14x
P/B
1.14x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$24.56M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.04
Operating Cash Flow
-$19M
Beta
0.85
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A
XBIT Overview
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how XBIT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
XBIT ($8.21) is overvalued by 24.94% relative to our estimate of its Fair Value price of $6.57 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
XBIT ($8.21) is not significantly undervalued (24.94%) relative to our estimate of its Fair Value price of $6.57 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
XBIT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more XBIT due diligence checks available for Premium users.
Be the first to know about important XBIT news, forecast changes, insider trades & much more!
XBIT News
Valuation
XBIT fair value
Fair Value of XBIT stock based on Discounted Cash Flow (DCF)
Price
$8.21
Fair Value
$6.57
Overvalued by
24.94%
XBIT ($8.21) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
XBIT ($8.21) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
XBIT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
XBIT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-10.14x
Industry
15.41x
Market
40.97x
XBIT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.14x
Industry
5.8x
XBIT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
XBIT's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.6M
Profit Margin
0%
XBIT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$226.6M
Liabilities
$7.8M
Debt to equity
0.04
XBIT's short-term assets ($201.72M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XBIT's short-term assets ($201.72M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XBIT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
XBIT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.4M
Investing
-$115.0k
Financing
$0.0
XBIT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
XBIT vs Biotech Stocks
Xbiotech Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.